|
1
|
Giaquinto AN, Sung H, Miller KD, Kramer
JL, Newman LA, Minihan A, Jemal A and Siegel RL: Breast cancer
statistics, 2022. CA Cancer J Clin. 72:524–541. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Morgan E, Rumgay H, Mafra A,
Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S
and Soerjomataram I: Current and future burden of breast cancer:
Global statistics for 2020 and 2040. Breast. 66:15–23. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Voduc KD, Cheang MCU, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tong CWS, Wu M, Cho WCS and To KKW: Recent
advances in the treatment of breast cancer. Front Oncol. 8:2272018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jamdade VS, Sethi N, Mundhe NA, Kumar P,
Lahkar M and Sinha N: Therapeutic targets of triple negative breast
cancer: A review. Br J Pharmacol. 172:4228–4237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raphael A, Salmon-Divon M, Epstein J,
Zahavi T, Sonnenblick A and Shachar SS: Alpelisib efficacy in
hormone receptor-positive HER2-negative PIK3CA-mutant advanced
breast cancer post-everolimus treatment. Genes (Basel).
29:17632022. View Article : Google Scholar
|
|
7
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16 (Suppl
1):S1–S11. 2011. View Article : Google Scholar
|
|
8
|
Robson M, Im SA, Senkus E, Xu B, Domchek
SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al:
Olaparib for metastatic breast cancer in patients with a germline
BRCA mutation. N Engl J Med. 377:523–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou Y, Peng Y and Li Z: Update on
prognostic and predictive biomarkers of breast cancer. Semin Diagn
Pathol. 39:322–332. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung C, Yeung VTY and Wong KCW:
Prognostic and predictive biomarkers with therapeutic targets in
breast cancer: A 2022 update on current developments, evidence, and
recommendations. J Oncol Pharm Pract. 15:1343–1360. 2023.
View Article : Google Scholar
|
|
11
|
Ovcaricek T, Takac I and Matos E:
Multigene expression signatures in early hormone receptor positive
HER 2 negative breast cancer. Radiol Oncol. 53:285–292. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: Discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, et
al: Increases of amphiregulin and transforming growth factor-alpha
in serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishikawa N, Daigo Y, Yasui W, Inai K,
Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel
serological and histochemical marker for lung cancer. Clin Cancer
Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kakiuchi S, Daigo Y, Ishikawa N, Furukawa
C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, et
al: Prediction of sensitivity of advanced non-small cell lung
cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato T, Daigo Y, Hayama S, Ishikawa N,
Yamabuki T, Ito T, Miyamoto M, Kondo S and Nakamura Y: A novel
human tRNA-dihydrouridine synthase involved in pulmonary
carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: identification of genes for prediction of
lymph-node metastasis and sensitivity to anticancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suzuki C, Daigo Y, Ishikawa N, Kato T,
Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical
role in human lung carcinogenesis through the activation of RHOA
and by involvement in the phosphoinositide 3-kinase/AKT pathway.
Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kakiuchi S, Daigo Y, Tsunoda T, Yano S,
Sone S and Nakamura Y: Genome-wide analysis of organ-preferential
metastasis of human small cell lung cancer in mice. Mol Cancer Res.
1:485–499. 2003.PubMed/NCBI
|
|
21
|
Taniwaki M, Daigo Y, Ishikawa N, Takano A,
Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression
profiles of small-cell lung cancers: Molecular signatures of lung
cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
22
|
Oshita H, Nishino R, Takano A, Fujitomo T,
Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y and
Daigo Y: RASEF is a novel diagnostic biomarker and a therapeutic
target for lung cancer. Mol Cancer Res. 11:937–951. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hayama S, Daigo Y, Yamabuki T, Hirata D,
Kato T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Phosphorylation and activation of cell division cycle associated 8
by aurora kinase B plays a significant role in human lung
carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K, Nishimura H, et al:
Characterization of SEZ6L2 cell-surface protein as a novel
prognostic marker for lung cancer. Cancer Sci. 97:737–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kato T, Sato N, Hayama S, Yamabuki T, Ito
T, Miyamoto M, Kondo S, Nakamura Y and Daigo Y: Activation of
Holliday junction recognizing protein involved in the chromosomal
stability and immortality of cancer cells. Cancer Res.
67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takano A, Ishikawa N, Nishino R, Masuda K,
Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kobayashi Y, Takano A, Miyagi Y, Tsuchiya
E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y and Daigo Y:
Cell division cycle-associated protein 1 overexpression is
essential for the malignant potential of colorectal cancers. Int J
Oncol. 44:69–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thang PM, Takano A, Yoshitake Y, Shinohara
M, Murakami Y and Daigo Y: Cell division cycle associated 1 as a
novel prognostic biomarker and therapeutic target for oral cancer.
Int J Oncol. 49:1385–1393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Daigo K, Takano A, Thang PM, Yoshitake Y,
Shinohara M, Tohnai I, Murakami Y, Maegawa J and Daigo Y:
Characterization of KIF11 as a novel prognostic biomarker and
therapeutic target for oral cancer. Int J Oncol. 52:155–165.
2018.PubMed/NCBI
|
|
30
|
Nakamura M, Takano A, Thang PM, Tsevegjav
B, Zhu M, Yokose T, Yamashita T, Miyagi Y and Daigo Y:
Characterization of KIF20A as a prognostic biomarker and
therapeutic target for different subtypes of breast cancer. Int J
Oncol. 57:277–288. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsevegjav B, Takano A, Zhu M, Yoshitake Y,
Shinohara M and Daigo Y: Holliday junction recognition protein as a
prognostic biomarker and therapeutic target for oral cancer. Int J
Oncol. 60:262022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu M, Takano A, Tsevegjav B, Yoshitake Y,
Shinohara M and Daigo Y: Characterization of Opa interacting
protein 5 as a new biomarker and therapeutic target for oral
cancer. Int J Oncol. 60:272022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hirokawa N, Noda Y and Okada Y: Kinesin
and dynein superfamily proteins in organelle transport and cell
division. Curr Opin Cell Biol. 10:60–73. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kanehira M, Katagiri T, Shimo A, Takata R,
Shuin T, Miki T, Fujioka T and Nakamura Y: Oncogenic role of
MPHOSPH1, a cancer-testis antigen specific to human bladder cancer.
Cancer Res. 67:3276–3285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin WF, Lin XL, Fu SW, Yang L, Tang CT,
Gao YJ, Chen HY and Ge ZZ: Pseudopod-associated protein KIF20B
promotes Gli1-induced epithelial-mesenchymal transition modulated
by pseudopodial actin dynamic in human colorectal cancer. Mol
Carcinog. 57:911–925. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu X, Zhou Y, Liu X, Peng A, Gong H,
Huang L, Ji K, Petersen RB, Zheng L and Huang K: MPHOSPH1: A
potential therapeutic target for hepatocellular carcinoma. Cancer
Res. 74:6623–6634. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen J, Zhao CC, Chen FR, Feng GW, Luo F
and Jiang T: KIF20B promotes cell proliferation and may be a
potential therapeutic target in pancreatic cancer. J Oncol.
2021:55724022021.PubMed/NCBI
|
|
38
|
Li ZY, Wang ZX and Li CC: Kinesin family
member 20B regulates tongue cancer progression by promoting cell
proliferation. Mol Med Rep. 19:2202–2210. 2019.PubMed/NCBI
|
|
39
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 7th edition. John Wiley
& Sons; 2011
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cao L and Niu Y: Triple negative breast
cancer: Special histological types and emerging therapeutic
methods. Cancer Biol Med. 17:293–306. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pearson GW: Control of invasion by
epithelial-to-mesenchymal transition programs during metastasis. J
Clin Med. 8:6462019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matsumoto-Taniura N, Pirollet F, Monroe R,
Gerace L and Westendorf JM: Identification of novel M phase
phosphoproteins by expression cloning. Mol Biol Cell. 7:1455–1469.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Abaza A, Soleilhac JM, Westendorf J, Piel
M, Crevel I, Roux A and Pirollet F: M phase phosphoprotein 1 is a
human plus-end-directed kinesin-related protein required for
cytokinesis. J Biol Chem. 278:27844–27852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kamimoto T, Zama T, Aoki R, Muro Y and
Hagiwara M: Identification of a novel kinesin-related protein,
KRMP1, as a target for mitotic peptidyl-prolyl isomerase Pin1. J
Biol Chem. 276:37520–37528. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cheng CW and Tse E: PIN1 in cell cycle
control and cancer. Front Pharmacol. 9:13672018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liou YC, Zhou XZ and Lu KP: Prolyl
isomerase Pin1 as a molecular switch to determine the fate of
phosphoproteins. Trends Biochem Sci. 36:501–514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T,
Petkova V and Lu KP: Pin1 is overexpressed in breast cancer and
cooperates with Ras signaling in increasing the transcriptional
activity of c-Jun towards cyclin D1. EMBO J. 20:3459–3472. 2001.
View Article : Google Scholar : PubMed/NCBI
|
